Barclays PLC Purchases 144,883 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Barclays PLC increased its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 496.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 174,061 shares of the company’s stock after buying an additional 144,883 shares during the period. Barclays PLC’s holdings in Janux Therapeutics were worth $7,907,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Summit Securities Group LLC purchased a new position in shares of Janux Therapeutics in the second quarter valued at about $29,000. Amalgamated Bank raised its stake in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd purchased a new position in Janux Therapeutics in the 2nd quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after buying an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $151,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 3.2 %

Shares of NASDAQ:JANX opened at $59.61 on Wednesday. The company has a market capitalization of $3.13 billion, a price-to-earnings ratio of -50.95 and a beta of 3.29. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $71.71. The firm’s 50-day moving average is $53.37 and its 200 day moving average is $46.92.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The company’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, equities analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 50,000 shares of the stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the transaction, the insider now owns 67,592 shares of the company’s stock, valued at approximately $3,106,528.32. This represents a 42.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 49,231 shares of Janux Therapeutics stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $46.45, for a total value of $2,286,779.95. Following the completion of the sale, the insider now owns 6,926 shares of the company’s stock, valued at $321,712.70. The trade was a 87.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 192,032 shares of company stock valued at $9,512,515. 29.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on JANX. BTIG Research upped their target price on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, December 3rd. HC Wainwright increased their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Stifel Nicolaus boosted their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Finally, UBS Group assumed coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target for the company. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.